CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

NCT04316364 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT537

EST. COMPLETION2023-04-15

Conditions

Non-Small-Cell Lung Cancer

Interventions

SHR-1316、Paclitaxel (Albumin Bound)、CarboplatinSHR-1316、ChemotherapeuticPlacebo、Chemotherapeutic

Study details

SPONSORJiangsu HengRui Medicine Co., Ltd.

START DATE2020-07-14

Related company profiles

Hengrui Medicine

600276.SS

Primary source

ClinicalTrials.gov record NCT04316364 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT04316364
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record